A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Progression-free Survival
Subjects may remain on study until disease progression
No
Helen Eliopoulos, MD
Study Director
Abbott
United States: Food and Drug Administration
M05-782
NCT00354562
February 2007
Name | Location |
---|---|
Site Ref # / Investigator 3572 | Birmingham, Alabama 35294-3300 |
Site Ref # / Investigator 4771 | Burbank, California 91505 |
Site Ref # / Investigator 3574 | Orange, California 92868-3298 |
Site Ref # / Investigator 3567 | Rancho Mirage, California 92270 |
Site Ref # / Investigator 3512 | Gurnee, Illinois 60031 |
Site Ref # / Investigator 3565 | Hackensack, New Jersey 07601 |
Site Ref # / Investigator 3569 | Buffalo, New York 14215 |
Site Ref # / Investigator 3511 | Cleveland, Ohio 44195 |
Site Ref # / Investigator 5237 | Ravenna, Ohio 44266 |
Site Ref # / Investigator 3551 | Crossville, Tennessee 38555 |
Site Ref # / Investigator 3549 | Knoxville, Tennessee 37920 |
Site Ref # / Investigator 3571 | Nashville, Tennessee 37232-6307 |
Site Ref # / Investigator 3510 | Weston, Wisconsin 54476 |